Venetoclax plus azacitidine in higher-risk myelodysplastic syndromes: a treatment-purpose framework for interpreting response depth
Venetoclax plus azacitidine has demonstrated substantial clinical activity in treatment-naïve higher-risk myelodysplastic syndromes (HR-MDS), including high rates of complete remission, marrow complete remission, and overall response. However, recent phase 3 experience indicates that greater response depth does not nec...